BIO-Europe: Dicot Pharma's CEO talks about moving the company's ED candidate into a phase 2a in multiple nordic countries - plus a stock market uplisting

blonca9
Nov 4, 2024
1 min read

Elin Trampe describes the unmet need the company believes exists for ED today, the history of their drug and how it was invented in Sweden's Uppsala University, and uplising to the First North Growth Market this week.

Brought to you by

Recent Posts

See All

AI News: Emeryville based Fauna Bio launched Fauna Brain, an AI platform that uses both internal and external data sets, and an analysis of the literature, to allow users to identify and score targets

AI News: Alameda based Infinimmune launched its GLIMPSE-1 antibody engineering platform that is based on a protein language model focused on native human antibody sequences

Draig Therapeutics launched from stealth today with a total of $140M investments to tackle neuropsych conditions. Co-Founder & Executive Chair Ruth McKernan tells the backstory and why she is excited

BIO-Europe: Dicot Pharma's CEO talks about moving the company's ED candidate into a phase 2a in multiple nordic countries - plus a stock market uplisting

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight